Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 1217 - 1224 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC5568 | PF-06463922 |
|
High affinity and selective ALK and ROS1 inhibitor (K<sub>i </sub>values are <0.02, <0.07 and 0.7 nM for ROS1, wild-type ALK and ALK-L1196M, respectively). Exhibits >100-fold selectivity for ROS1 over a panel of 204 other kinases. Inhibits proliferation of BaF3 cells containing crizotinib-resistant ROS1 mutation <em>in vitro</em>. Inhibits tumor growth in relevant mouse models. Orally available and brain penetrant.
|
|
| BCC5569 | RBC8 |
|
RalA and RalB GTPase inhibitor (EC<sub>50</sub> ~3.5 <span class='symbol'>μ</span>M). Inhibits the binding of Ral to RaLBP1. Exhibits no detectable inhibition of Ras or RhoA activity. Suppresses growth of xenograft tumors in mice. Cell permeable.
|
|
| BCC5579 | OF-1 |
|
Selective BRPF1B and BRPF2 bromodomain inhibitor (K<sub>d</sub> values are 100 and 500 nM respectively). Exhibits 39-fold selectivity for BRPF1B and BRPF2 over BRD4. Accelerates FRAP recovery at 5 <span class='symbol'>μ</span>M in a BRPF2 FRAP assay.
|
|
| BCC5581 | CCG-1423 |
|
Rho/SRF pathway inhibitor; stimulates apoptosis of a melanoma cell line overexpressing RhoC (A375M2). Suppresses Rho-dependent invasion of PC-3 prostate cancer cells <em>in vitro</em> and inhibits lysophosphatidic acid-induced DNA synthesis in PC-3 prostate cancer cells. When used in combination with Retinoic acid,LY 294002 and Pyridone 6, it induces intermediate mesoderm differentiation from ESCs.
|
|
| BCC5584 | Indoximod (NLG-8189) |
|
Indoleamine 2,3-dioxygenase (IDO) inhibitor (IC<sub>50</sub> = 7 <span class='symbol'>μ</span>M); disrupts tryptophan catabolism. Enhances the antitumor and antiviral immunoresponses of CD8+ T-cells <em>in vitro</em>. Reduces tumor volume in mice with xenografts overexpressing IDO.
|
|
| BCC5589 | PF-06447475 |
|
Potent LRRK2 inhibitor (IC<sub>50</sub> = 3 nM). Attenuates <span class='symbol'>α</span>-synuclein-induced dopaminergic neurodegeneration and neuroinflammation in G2019S-LRRK2 expressing rats. Also neuroprotective in wild type rats. Brain penetrant.
|
|
| BCC5597 | GSK 5959 |
|
Potent and selective BRPF1 bromodomain inhibitor (IC50 = 80 nM). Exhibits >100-fold selectivity for BRPF1 over a panel of 35 other bromodomains, including BRPF2/3 and BET family bromodomains. Inhibits BRPF1 interaction with histone H3.3. Cell permeable.
|
|
| BCC5598 | OXF BD 02 |
|
Selective inhibitor of the first bromodomain of BRD4 (BRD4(1)) (IC50 = 382 nM). Exhibits 2-3-fold selectivity for BRD4(1) over the CBP bromodomain and has little affinity for a range of other bromodomains. Reduces viability of lung adenocarcinoma cell lines and attenuates proliferation of MV-4-11 leukemia cells. Cell permeable.
|
|